Works matching IS 00099236 AND DT 2024 AND VI 115
Results: 179
Moving the Needle for Oncology Dose Optimization: A Call for Action.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1187, doi. 10.1002/cpt.3263
- By:
- Publication type:
- Article
Highlights.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1198, doi. 10.1002/cpt.3262
- Publication type:
- Article
ASCPT News.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1200, doi. 10.1002/cpt.3261
- Publication type:
- Article
In This Issue.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1185, doi. 10.1002/cpt.3259
- Publication type:
- Article
Artificial Intelligence and Disease Modeling: Focus on Neurological Disorders.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1208, doi. 10.1002/cpt.3253
- By:
- Publication type:
- Article
Clinical Pharmacology Considerations for the "Off‐the‐Shelf" Allogeneic Cell Therapies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1233, doi. 10.1002/cpt.3241
- By:
- Publication type:
- Article
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1450, doi. 10.1002/cpt.3240
- By:
- Publication type:
- Article
A Benefit–Risk Conceptual Framework for Biologic Use During Pregnancy: A Mini‐Review.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1251, doi. 10.1002/cpt.3239
- By:
- Publication type:
- Article
Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1441, doi. 10.1002/cpt.3237
- By:
- Publication type:
- Article
Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1428, doi. 10.1002/cpt.3236
- By:
- Publication type:
- Article
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1418, doi. 10.1002/cpt.3235
- By:
- Publication type:
- Article
Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1212, doi. 10.1002/cpt.3230
- By:
- Publication type:
- Article
Genetic Determinants of Thiazide‐Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances – A Genome‐Wide Evaluation of the UK Biobank.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1408, doi. 10.1002/cpt.3229
- By:
- Publication type:
- Article
The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1400, doi. 10.1002/cpt.3227
- By:
- Publication type:
- Article
Algorithmic Identification of Treatment‐Emergent Adverse Events From Clinical Notes Using Large Language Models: A Pilot Study in Inflammatory Bowel Disease.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1391, doi. 10.1002/cpt.3226
- By:
- Publication type:
- Article
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1383, doi. 10.1002/cpt.3225
- By:
- Publication type:
- Article
How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1372, doi. 10.1002/cpt.3224
- By:
- Publication type:
- Article
Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1258, doi. 10.1002/cpt.3223
- By:
- Publication type:
- Article
Impact of Drug Recalls on Patients in The Netherlands: A 5‐Year Retrospective Data Analysis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1365, doi. 10.1002/cpt.3220
- By:
- Publication type:
- Article
Real‐World Evidence to Inform Regulatory Decision Making: A Scoping Review.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1269, doi. 10.1002/cpt.3218
- By:
- Publication type:
- Article
Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1358, doi. 10.1002/cpt.3217
- By:
- Publication type:
- Article
Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1346, doi. 10.1002/cpt.3216
- By:
- Publication type:
- Article
Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1336, doi. 10.1002/cpt.3215
- By:
- Publication type:
- Article
Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1204, doi. 10.1002/cpt.3214
- By:
- Publication type:
- Article
Oral SSTR5 Antagonist SCO‐240 for Growth Hormone Stimulation: A Phase I Single‐Dose Study in Healthy Individuals.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1326, doi. 10.1002/cpt.3212
- By:
- Publication type:
- Article
Genetic Prediction of Smoking Cessation Medication Side Effects: A Genome‐Wide Investigation of Abnormal Dreams on Varenicline.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1277, doi. 10.1002/cpt.3210
- By:
- Publication type:
- Article
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1316, doi. 10.1002/cpt.3207
- By:
- Publication type:
- Article
SGLT‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1304, doi. 10.1002/cpt.3194
- By:
- Publication type:
- Article
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1293, doi. 10.1002/cpt.3189
- By:
- Publication type:
- Article
Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1282, doi. 10.1002/cpt.3181
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1177, doi. 10.1002/cpt.2943
- Publication type:
- Article
Patient‐Centric Clinical Pharmacology: A Journey from Discovery to Recovery.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 928, doi. 10.1002/cpt.3243
- By:
- Publication type:
- Article
ASCPT News.
- Published in:
- 2024
- Publication type:
- Proceeding
In This Issue.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 915, doi. 10.1002/cpt.3233
- Publication type:
- Article
Highlights.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 920, doi. 10.1002/cpt.3232
- Publication type:
- Article
Best Practices for Pharmacokinetic Studies of New Chemical Entities.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 917, doi. 10.1002/cpt.3231
- By:
- Publication type:
- Article
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 954, doi. 10.1002/cpt.3213
- By:
- Publication type:
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 988, doi. 10.1002/cpt.3192
- By:
- Publication type:
- Article
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1162, doi. 10.1002/cpt.3190
- By:
- Publication type:
- Article
Corrections to "Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions".
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1175, doi. 10.1002/cpt.3187
- Publication type:
- Article
Pharmacotherapy to Improve Cognitive Functioning After Acquired Brain Injury: A Meta‐Analysis and Meta‐Regression.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 971, doi. 10.1002/cpt.3186
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A (LY3509754): A Phase I Randomized Placebo‐Controlled Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1152, doi. 10.1002/cpt.3185
- By:
- Publication type:
- Article
Relationships of Proton Pump Inhibitor‐Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1141, doi. 10.1002/cpt.3183
- By:
- Publication type:
- Article
Concomitant Use of Sodium‐Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1132, doi. 10.1002/cpt.3182
- By:
- Publication type:
- Article
A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1122, doi. 10.1002/cpt.3180
- By:
- Publication type:
- Article
Quantitative Model‐Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1114, doi. 10.1002/cpt.3175
- By:
- Publication type:
- Article
Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1105, doi. 10.1002/cpt.3174
- By:
- Publication type:
- Article
Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1092, doi. 10.1002/cpt.3173
- By:
- Publication type:
- Article
Amelioration of Acute Radiation Dermatitis in Breast Cancer Patients by a Bioadhesive Barrier‐Forming Gel (Episil): A Single‐Center, Open, Parallel, Randomized, Phase I/II Controlled Trial.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1085, doi. 10.1002/cpt.3171
- By:
- Publication type:
- Article
A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 5, p. 1075, doi. 10.1002/cpt.3170
- By:
- Publication type:
- Article